8-K: Cassava Sciences Cleared by DOJ in Research Misconduct Inquiry

Cassava Sciences announced the closure of the U.S. Department of Justice's inquiry into research misconduct allegations, ending all federal investigations.

Summary

• The U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into Cassava Sciences regarding allegations of research misconduct.
• This inquiry was related to the indictment in United States v. Wang, which was dismissed with prejudice by the DOJ on October 23, 2025.
• The closure of the DOJ inquiry, along with a previously disclosed settlement with the U.S. Securities and Exchange Commission (SEC) in September 2024, concludes all federal investigations into the Company.
• Cassava Sciences paid a monetary penalty to the SEC without admitting or denying the negligence-based disclosure charges.
• The Company fully cooperated with both the DOJ and SEC investigations.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, as the resolution of significant federal investigations removes a major source of uncertainty and potential liability, allowing the company to focus on its core drug development activities.

Positives

• The U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into Cassava Sciences, removing a significant legal overhang.
• The dismissal of the related indictment in United States v. Wang with prejudice by the DOJ on October 23, 2025, further strengthens the company's position.
• All federal investigations by the DOJ and SEC into the Company have now concluded.
• Management expressed a renewed focus on developing a novel treatment for TSC-related epilepsy.

Negatives

• Cassava Sciences previously settled negligence-based disclosure charges with the U.S. Securities and Exchange Commission (SEC) in September 2024.
• The Company paid a monetary penalty as part of the SEC settlement.
• The existence of these investigations, even if now closed, highlights past scrutiny regarding research misconduct allegations and disclosure practices.

Risks

• Risks inherent in drug discovery and development are significant.
• Specific risks to Cassava Sciences are detailed in the Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• Clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger-scale clinical trials and do not ensure regulatory approval.
• Research and development activities are long, complex, costly, and involve a high degree of risk.
• Investors are cautioned not to invest unless prepared to sustain a total loss of their investment due to the fundamental risk in drug discovery and development.
• Pharmaceutical assets under development are investigational product candidates and have not been approved for use in any medical indication.

Future Outlook

Cassava Sciences plans to continue focusing its efforts on developing a novel treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy, and potentially other central nervous system (CNS) indications, including simufilam.

Management Comments

• "We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders."
• "As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy."

Industry Context

StockSavvy.ai notes that the closure of federal investigations, particularly from the DOJ and SEC, is a significant de-risking event for any biotechnology company, especially one involved in novel drug development for CNS disorders. Such legal overhangs can severely impact investor confidence and the ability to raise capital or attract partnerships. This resolution allows Cassava Sciences to potentially re-focus resources and attention solely on its clinical programs, which is crucial in the highly competitive and capital-intensive biotech sector.

Legal Proceedings

• U.S. Department of Justice Fraud Section (DOJ) inquiry into allegations of research misconduct, now closed.
• Indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.), dismissed with prejudice by DOJ on October 23, 2025.
• Settlement with the U.S. Securities and Exchange Commission (SEC) in September 2024 regarding negligence-based disclosure charges, involving a monetary penalty.

Stakeholder Impact

• Shareholders: Likely positive impact due to the removal of legal uncertainty and potential liabilities, which could improve investor confidence and potentially the stock price.
• Management/Employees: Can now fully focus on core business objectives without the distraction and burden of ongoing federal investigations.
• Customers/Patients: Continued focus on developing treatments for CNS disorders, particularly TSC-related epilepsy, could benefit future patients.
• Regulatory Authorities: The company's cooperation with investigations and resolution of issues may improve its standing with regulatory bodies.

Next Steps

• Continue to focus efforts on developing a novel treatment for TSC-related epilepsy.
• Potentially pursue other indications for investigational treatments like simufilam.

Key Dates

Recommendation

The complete resolution of both DOJ and SEC investigations removes a substantial overhang that has likely suppressed the stock price. With these significant legal uncertainties behind it, Cassava Sciences can now fully dedicate its resources and investor focus to its core mission of developing novel CNS treatments, particularly for TSC-related epilepsy. This de-risking event makes the stock significantly more attractive for long-term investors, assuming the underlying drug development programs show promise.

Keywords

Cassava Sciences, SAVA, DOJ investigation, SEC settlement, research misconduct, biotechnology, CNS disorders, TSC-related epilepsy, drug development, simufilam, regulatory closure